Hypofractionated radiation therapy for endometrial and cervical cancers
Official title: Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers (HERA Trial)
Run by Jonsson Comprehensive Cancer Center · NCT06538337 · Data updated 2026-11-12
This study is testing a new way of giving radiation therapy in larger doses over 5 days to see if it helps people who have had surgery for endometrial or cervical cancer feel better while making treatment easier.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 60 (estimated) |
| Sponsor | Jonsson Comprehensive Cancer Center Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Los Angeles, California) |
| Status | Recruiting |
| Started | July 24, 2024 |
| Main results expected | July 26, 2031 |
| Study ends | July 26, 2032 |
| Registry record updated | August 20, 2026 |
| Trial ID | NCT06538337 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with histologically confirmed endometrial or cervical cancer who have undergone surgical resection and meet specific FIGO staging criteria.
✕Probably not a fit
Patients who are undergoing concurrent chemotherapy or have a history of prior irradiation to the treatment area may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the use of hypo-fractionated external beam radiotherapy with adaptive planning for patients who have undergone surgery for endometrial or cervical cancer. The approach involves delivering a total of 30 Gy in 5 larger doses, utilizing MRI or CT guidance to enhance treatment precision and tolerability. Participants will receive treatment over a span of 5 days, followed by regular follow-up appointments for up to 5 years to monitor outcomes and side effects. The goal is to determine if this method can reduce treatment burden while maintaining effectiveness.
Why it matters
Potential benefit: If successful, this approach could lead to fewer radiation sessions with comparable side effects, improving patient comfort and treatment adherence.
How similar studies have gone: Previous studies have shown that adaptive planning in radiation therapy can significantly improve treatment outcomes, suggesting potential success for this novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically confirmed endometrial or cervical cancer * Surgical resection of the primary tumor * International Federation of Gynecology and Obstetrics (FIGO) Stage IA-IVB endometrial cancer OR FIGO Stage IA-IIA cervical cancer that meets indications for receiving adjuvant pelvic radiotherapy alone as standard of care * Age ≥ 18 years old * Karnofsky performance status (KPS) ≥ 60 or Eastern Cooperative Oncology Group (ECOG) 0-2 Exclusion Criteria: * Must not meet indications for receiving concurrent chemotherapy as standard of care * Active treatment of a separate malignancy * History of prior irradiation to the area to be treated
Where it's running
-
University of California at Los Angeles
Los Angeles, California, United States Recruiting
Study contacts
- Principal investigator: Puja S. Venkat, MD — University of California at Los Angeles
- Study coordinator: Christy Palodichuk
- Email: cpalodichuk@mednet.ucla.edu
- Phone: 310-794-2971
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
One-Finger Technique to identify the left upper ureter during para-aortic lymphadenectomy
This study tests a new surgical method to help surgeons find the left upper ureter during open para-aortic lymphadenectomy in women with gynecologic cancers.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
Stellate ganglion block and dexmedetomidine for better sleep after gynecologic laparoscopy
The study tests whether giving a preoperative stellate ganglion block plus intraoperative dexmedetomidine improves sleep after laparoscopic gynecologic surgery in women.
-
First-in-human test of HH160 in people with advanced solid tumors
HH160 is being tested to see if it is safe and how it behaves in the body, to see if it has early signs of helping various advanced cancers in adults.
-
Online adaptive radiotherapy vs standard radiotherapy after surgery for cervical or endometrial cancer
A national, multi-center study will test whether online adaptive radiotherapy can reduce side effects and improve quality of life compared with standard radiotherapy in adults after surgery for cervical or endometrial cancer.
-
CAIX-targeted 18F-T2 PET/CT imaging in solid tumors
This study tests a CAIX-specific radioactive tracer to see if PET/CT can help visualize solid tumors and checks safety and radiation exposure in adults with certain cancers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.